ACM
BPMC

Aquilo Capital Management’s Blueprint Medicines BPMC Stock Holding History

Aquilo Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-83,926
Closed -$7.43M – 6
2025
Q1 		$7.43M Sell
83,926
-45,674
-35% -$4.46M 13.32% 2
2024
Q4 		$11.3M Buy
129,600
+5,000
+4% +$458K 17.04% 2
2024
Q3 		$11.5M Buy
124,600
+10,000
+9% +$993K 8.74% 3
2024
Q2 		$12.4M Sell
114,600
-67,551
-37% -$6.76M 11.91% 2
2024
Q1 		$17.3M Sell
182,151
-72,676
-29% -$6.23M 12.95% 3
2023
Q4 		$23.5M Sell
254,827
-124,263
-33% -$8.05M 14.65% 2
2023
Q3 		$19M Sell
379,090
-69,897
-16% -$3.74M 17.25% 2
2023
Q2 		$28.4M Sell
448,987
-173,842
-28% -$9.45M 15.72% 2
2023
Q1 		$28M Buy
622,829
+41,061
+7% +$1.85M 11.61% 2
2022
Q4 		$25.5M Buy
581,768
+57,500
+11% +$2.76M 9.57% 3
2022
Q3 		$34.5M Sell
524,268
-192,271
-27% -$12.3M 12.45% 3
2022
Q2 		$36.2M Sell
716,539
-65,000
-8% -$3.81M 12.35% 3
2022
Q1 		$49.9M Buy
781,539
+136,000
+21% +$9.76M 7.34% 3
2021
Q4 		$69.1M Buy
645,539
+123,866
+24% +$13M 7.84% 3
2021
Q3 		$53.6M Buy
521,673
+73,161
+16% +$6.81M 9.74% 3
2021
Q2 		$39.5M Buy
448,512
+25,500
+6% +$2.34M 10.25% 3
2021
Q1 		$41.1M Buy
423,012
+43,000
+11% +$4.29M 7.43% 5
2020
Q4 		$42.6M Sell
380,012
-5,715
-1% -$602K 8.86% 4
2020
Q3 		$35.8M Buy
385,727
+70,698
+22% +$5.44M 3.79% 4
2020
Q2 		$24.6M Buy
+315,029
New +$21.3M 4.95% 6
2019
Q2 		– Sell
-30,618
Closed -$2.45M – 14
2019
Q1 		$2.45M Buy
+30,618
New +$2.26M 1.08% 13

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aquilo Capital Management's BPMC Position: Q2 2025 in Review

Aquilo Capital Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 83,926 shares — an estimated $7.43M sold.

Aquilo Capital Management first reported a position in BPMC in Q1 2019 and held it in 21 quarters. The position peaked at $69.1M in Q4 2021. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Aquilo Capital Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Aquilo Capital Management sold 83,926 Blueprint Medicines shares in Q2 2025, an estimated $7.43M.
  • Aquilo Capital Management first reported a position in Blueprint Medicines in Q1 2019 and held it in 21 quarters.
  • Aquilo Capital Management's Blueprint Medicines position peaked at $69.1M in Q4 2021.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Aquilo Capital Management's 13F filing for Q2 2025.